Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-03-18 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated March 18, 2015, announcing that Onxeo S.A. received a new patent grant for its drug Validive® in Japan. It details the significance of this patent, provides clinical trial updates (Phase II results), and discusses the market potential. This type of announcement, focusing on intellectual property, clinical milestones, and strategic updates, is characteristic of general corporate news releases intended for investors, but it does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or DIV (Dividend Notice). Since it is a specific announcement about intellectual property consolidation and market strategy, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate news, or potentially IP (Intellectual Property) if that category were broader. Given the provided definitions, RNS serves as the most appropriate fallback for a significant, non-periodic corporate announcement that isn't explicitly covered by the other codes (like M&A, Financing, or Director Dealing). However, since the core subject is the consolidation of Intellectual Property, and 'IP' is an available code, I will check if 'IP' fits better. The definition for 'IP' is 'Investor Presentation'. This document is clearly not an Investor Presentation. Therefore, RNS (Regulatory Filings/General Announcement) is the most suitable classification for this specific press release about a patent grant.
2015-03-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated March 18, 2015, announcing that Onxeo SA obtained a new patent for its product Validive® in Japan, extending protection until 2029. It discusses clinical trial progress (Phase II results) and market potential. This type of announcement, focusing on intellectual property, clinical milestones, and business updates, is characteristic of an Earnings Release (ER) if it were summarizing period results, or a general Regulatory Filing (RNS). However, since it is a specific, material business update (patent grant and clinical progress) that is not a full financial report (10-K, IR) or a management discussion (MDA), and it is not a proxy/voting document (DEF 14A, PSI), the most appropriate classification for a significant, non-standard corporate announcement that isn't explicitly covered by other codes is the general Regulatory Filings category (RNS), as it serves as a broad disclosure mechanism for material, non-financial-statement news. Given the content is a specific corporate action/update rather than a general regulatory filing fallback, and it doesn't fit ER (as it's not focused on period results), or IP (as it's a press release about IP, not the IP document itself), RNS is the best fit among the available options for a material press release.
2015-03-18 French
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document explicitly states its purpose in the title: "Disclosure of total number of voting rights and number of shares in the capital at February 28, 2015". It cites French commercial code and AMF regulations, which mandate such disclosures. This type of filing reports the total outstanding shares and voting rights, often required periodically or upon significant changes. This content aligns most closely with regulatory reporting concerning share capital and voting structure. While it is a specific regulatory disclosure, it does not fit perfectly into the defined categories like 10-K, ER, or IR. It is a specific regulatory announcement regarding share capital structure. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit as it deals directly with the number of shares and voting rights, which are components of the capital structure. However, since it is a routine disclosure of the *total number* of rights rather than an announcement of a *change* (like an issue or buyback), and it is a specific regulatory notice, 'Regulatory Filings' (RNS) is a strong fallback. Reviewing the definitions, 'SHA' covers 'new share issues, stock splits, or other capital changes.' This document reports the *current state* of shares/rights, not a change event. Therefore, as a specific regulatory disclosure that doesn't fit the primary financial reports or specific corporate actions, RNS (Regulatory Filings) is the most appropriate general category for this mandatory disclosure.
2015-03-05 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 28 février 2015" (Information relating to the total number of voting rights and shares comprising the capital as of February 28, 2015). It explicitly references compliance with the French Commercial Code (Article L. 233-8 II) and the AMF General Regulation (Article 223-16), which mandates the disclosure of total voting rights and shares outstanding, typically on the 15th of each month or the last trading day of the month. This specific disclosure relates to the total number of shares and voting rights, which is a mandatory regulatory filing concerning capital structure and shareholder information, but it is not a standard SEC form like 10-K or a general earnings release. Among the provided codes, this type of mandatory disclosure about the total number of shares and voting rights is best categorized as a specific regulatory announcement concerning capital/share structure or a general regulatory filing. Since it details the total number of shares and voting rights, it is closely related to capital structure changes or mandatory reporting. Given the options, it fits best under 'Declaration of Voting Results & Voting Rights Announcements' (DVA) as it explicitly deals with voting rights, or potentially 'Regulatory Filings' (RNS) if DVA is too specific to post-meeting results. However, the core content is the monthly disclosure of voting rights, making DVA the most precise fit among the choices provided for disclosures related to voting rights counts.
2015-03-05 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of three new senior executives (Director of Alliance Management, CSO/Head of R&D, and Director of Human Resources) and noting the departure of another executive. This content directly relates to changes in the company's senior leadership and board structure. According to the definitions, this aligns perfectly with the 'Board/Management Information' category (Code: MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns specific management changes.
2015-02-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document text is a press release dated February 10, 2015, announcing significant appointments to the senior management team of Onxeo SA (Elisabeth Carstensen, Graham Dixon, Audrey Legentil-Duméry) and noting the departure of another executive. This content directly relates to changes in the company's board of directors or senior management personnel. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2015-02-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.